Authors

Robert Tindle

PhD, Emeritus Professor in Immunology, University of Queensland, Faculty of Science, Brisbane, Qld; Director (Retired), Sir Albert Sakzewski Virus Research Centre, Royal Children’s Hospital, Brisbane, Qld; Director, Clinical Medical Virology Centre, University of Queensland, Brisbane, Qld

Tumour-agnostic immunotherapy for rare and uncommon cancers: The patient’s dilemma

This viewpoint discusses immune checkpoint inhibitor (ICI) drugs for the treatment of rare and less common cancers.